Association between apolipoprotein E polymorphism and serum lipid and apolipoprotein levels with Alzheimer's disease

Asad Vaisi Raygani, Zohreh Rahimi, Hadi Kharazi, Haidar Tavilani, Tayebeh Pourmotabbed

Research output: Contribution to journalArticle

40 Citations (Scopus)

Abstract

We have recently demonstrated that apolipoprotein E (APOE)-ε4 allele is a risk factor for Alzheimer disease (AD) in Tehran, Iran. The current study specifically aimed to examine whether APOE polymorphism in association with serum lipids-apolipoprotein level is a risk factor for AD in a population from Tehran, Iran. APOE polymorphism and plasma lipids, apoA1, apoB and lipoprotein (a) (Lp(a)) levels were determined in 94 AD patients and 111matched controls. Our study demonstrated a significant association between APOE polymorphism and the level of plasma lipids and apolipoprotein with AD in this population. The AD subjects had significantly lower apoA1 (p < 0.001) and HDL-C (p < 0.01) and higher apoB (p = 0.01) and LDL-C (p = 0.02) levels than that of the control group. The AD subjects carrying APOE-ε4 allele had lower plasma apoA1 (t = 5.2, p < 0.002) and HDL-C level (t = 2.7, p = 0.01) but had higher plasma apoB (t = -5.4, p < 0.002), LDL-C (t = -4.6, p = 0.005) and total cholesterol (TC) (t = -2.7, p = 0.01) than that of the non APOE-ε4 carriers. These results indicated that AD patients with APOE-ε4 allele has a distinct plasma lipid profile and carrier of this allele with low levels of apoA1 and HDL-C may be more susceptible to AD.

Original languageEnglish (US)
Pages (from-to)68-72
Number of pages5
JournalNeuroscience Letters
Volume408
Issue number1
DOIs
StatePublished - Nov 6 2006

Fingerprint

Apolipoproteins
Apolipoproteins E
Alzheimer Disease
Apolipoprotein E4
Lipids
Serum
Apolipoproteins B
Alleles
Iran
Lipoprotein(a)
Population
Cholesterol
Control Groups

All Science Journal Classification (ASJC) codes

  • Neuroscience(all)

Cite this

Association between apolipoprotein E polymorphism and serum lipid and apolipoprotein levels with Alzheimer's disease. / Raygani, Asad Vaisi; Rahimi, Zohreh; Kharazi, Hadi; Tavilani, Haidar; Pourmotabbed, Tayebeh.

In: Neuroscience Letters, Vol. 408, No. 1, 06.11.2006, p. 68-72.

Research output: Contribution to journalArticle

Raygani, Asad Vaisi ; Rahimi, Zohreh ; Kharazi, Hadi ; Tavilani, Haidar ; Pourmotabbed, Tayebeh. / Association between apolipoprotein E polymorphism and serum lipid and apolipoprotein levels with Alzheimer's disease. In: Neuroscience Letters. 2006 ; Vol. 408, No. 1. pp. 68-72.
@article{f7807e746b71439eb5adbb622f3d80d7,
title = "Association between apolipoprotein E polymorphism and serum lipid and apolipoprotein levels with Alzheimer's disease",
abstract = "We have recently demonstrated that apolipoprotein E (APOE)-ε4 allele is a risk factor for Alzheimer disease (AD) in Tehran, Iran. The current study specifically aimed to examine whether APOE polymorphism in association with serum lipids-apolipoprotein level is a risk factor for AD in a population from Tehran, Iran. APOE polymorphism and plasma lipids, apoA1, apoB and lipoprotein (a) (Lp(a)) levels were determined in 94 AD patients and 111matched controls. Our study demonstrated a significant association between APOE polymorphism and the level of plasma lipids and apolipoprotein with AD in this population. The AD subjects had significantly lower apoA1 (p < 0.001) and HDL-C (p < 0.01) and higher apoB (p = 0.01) and LDL-C (p = 0.02) levels than that of the control group. The AD subjects carrying APOE-ε4 allele had lower plasma apoA1 (t = 5.2, p < 0.002) and HDL-C level (t = 2.7, p = 0.01) but had higher plasma apoB (t = -5.4, p < 0.002), LDL-C (t = -4.6, p = 0.005) and total cholesterol (TC) (t = -2.7, p = 0.01) than that of the non APOE-ε4 carriers. These results indicated that AD patients with APOE-ε4 allele has a distinct plasma lipid profile and carrier of this allele with low levels of apoA1 and HDL-C may be more susceptible to AD.",
author = "Raygani, {Asad Vaisi} and Zohreh Rahimi and Hadi Kharazi and Haidar Tavilani and Tayebeh Pourmotabbed",
year = "2006",
month = "11",
day = "6",
doi = "10.1016/j.neulet.2006.08.048",
language = "English (US)",
volume = "408",
pages = "68--72",
journal = "Neuroscience Letters",
issn = "0304-3940",
publisher = "Elsevier Ireland Ltd",
number = "1",

}

TY - JOUR

T1 - Association between apolipoprotein E polymorphism and serum lipid and apolipoprotein levels with Alzheimer's disease

AU - Raygani, Asad Vaisi

AU - Rahimi, Zohreh

AU - Kharazi, Hadi

AU - Tavilani, Haidar

AU - Pourmotabbed, Tayebeh

PY - 2006/11/6

Y1 - 2006/11/6

N2 - We have recently demonstrated that apolipoprotein E (APOE)-ε4 allele is a risk factor for Alzheimer disease (AD) in Tehran, Iran. The current study specifically aimed to examine whether APOE polymorphism in association with serum lipids-apolipoprotein level is a risk factor for AD in a population from Tehran, Iran. APOE polymorphism and plasma lipids, apoA1, apoB and lipoprotein (a) (Lp(a)) levels were determined in 94 AD patients and 111matched controls. Our study demonstrated a significant association between APOE polymorphism and the level of plasma lipids and apolipoprotein with AD in this population. The AD subjects had significantly lower apoA1 (p < 0.001) and HDL-C (p < 0.01) and higher apoB (p = 0.01) and LDL-C (p = 0.02) levels than that of the control group. The AD subjects carrying APOE-ε4 allele had lower plasma apoA1 (t = 5.2, p < 0.002) and HDL-C level (t = 2.7, p = 0.01) but had higher plasma apoB (t = -5.4, p < 0.002), LDL-C (t = -4.6, p = 0.005) and total cholesterol (TC) (t = -2.7, p = 0.01) than that of the non APOE-ε4 carriers. These results indicated that AD patients with APOE-ε4 allele has a distinct plasma lipid profile and carrier of this allele with low levels of apoA1 and HDL-C may be more susceptible to AD.

AB - We have recently demonstrated that apolipoprotein E (APOE)-ε4 allele is a risk factor for Alzheimer disease (AD) in Tehran, Iran. The current study specifically aimed to examine whether APOE polymorphism in association with serum lipids-apolipoprotein level is a risk factor for AD in a population from Tehran, Iran. APOE polymorphism and plasma lipids, apoA1, apoB and lipoprotein (a) (Lp(a)) levels were determined in 94 AD patients and 111matched controls. Our study demonstrated a significant association between APOE polymorphism and the level of plasma lipids and apolipoprotein with AD in this population. The AD subjects had significantly lower apoA1 (p < 0.001) and HDL-C (p < 0.01) and higher apoB (p = 0.01) and LDL-C (p = 0.02) levels than that of the control group. The AD subjects carrying APOE-ε4 allele had lower plasma apoA1 (t = 5.2, p < 0.002) and HDL-C level (t = 2.7, p = 0.01) but had higher plasma apoB (t = -5.4, p < 0.002), LDL-C (t = -4.6, p = 0.005) and total cholesterol (TC) (t = -2.7, p = 0.01) than that of the non APOE-ε4 carriers. These results indicated that AD patients with APOE-ε4 allele has a distinct plasma lipid profile and carrier of this allele with low levels of apoA1 and HDL-C may be more susceptible to AD.

UR - http://www.scopus.com/inward/record.url?scp=33749066121&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33749066121&partnerID=8YFLogxK

U2 - 10.1016/j.neulet.2006.08.048

DO - 10.1016/j.neulet.2006.08.048

M3 - Article

VL - 408

SP - 68

EP - 72

JO - Neuroscience Letters

JF - Neuroscience Letters

SN - 0304-3940

IS - 1

ER -